AJANTA PHARMA LTD. - 532331 - Participation In Investor Conference
Pl. find enclosed schedule of participation in investor conference17-08-2023
17-08-2023
AJANTA PHARMA LTD. - 532331 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for UTI Mutual Fund & PACs09-08-2023
AJANTA PHARMA LTD. - 532331 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Issue of Letter of confirmation in lieu of duplicate share certificate07-08-2023
AJANTA PHARMA LTD. - 532331 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
PFA herewith written transcript of earnings call held on 27th July 2023.02-08-2023
Buy Ajanta Pharma; target of Rs 1580: ICICI Securities
ICICI Securities is bullish on Ajanta Pharma recommended buy rating on the stock with a target price of Rs 1580 in its research report dated July 29, 2023.01-08-2023
AJANTA PHARMA LTD. - 532331 - Record Date For Dividend
Board fixes Friday, 4th August 2023 as record date.28-07-2023
Ajanta Pharma's shares surge by 9.55%
The company's revenue was up 7.37 per cent to 1,021.04 crore compared to 950.93 crore last year28-07-2023
AJANTA PHARMA LTD. - 532331 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation regarding issue of letter of confirmation in lieu of duplicate share certificate28-07-2023
AJANTA PHARMA LTD. - 532331 - Announcement under Regulation 30 (LODR)-Newspaper Publication
PFA herewith results published in Business Standard & Navakal.28-07-2023
Q1FY24 Quarterly Result Announced for Ajanta Pharma Ltd.
Pharmaceuticals company Ajanta Pharma announced Q1FY24 results: Revenue from operations at Rs 1,021 crore in Q1FY24 against Rs 951 crore in Q1FY23; up 7% YoY EBITDA at Rs 271 crore in Q1FY24 against Rs 222 crore in Q1FY23; up 22%; EBITDA at 26% YoY Profit after tax at Rs 208 crore in Q1FY24 against Rs 175 crore in Q1FY23; up 19%; PAT at 20% YoY R&D; expenses were Rs 55 crore, 5% of revenue. Board of Directors has approved 1st interim dividend of Rs 315 crore for the year FY24. It translated into Rs 25 per share (1250%) for each Rs 2 face value share. This total dividend of Rs 25 per share includes a regular dividend of Rs 10 per share, and an additional Rs 15 per share, distributed as a special dividend on the commemoration of 50 years of the momentous journey of the Company. Result PDF28-07-2023